By vgreene, 15 April, 2020 Observational cohort study: 181 hospitalized pts (median age 60y, 84 treated w/in 48h after admission w/ HCQ 600 mg/day; 97 not treated) requiring O2 by mask or NC; excl use of other drugs (TCZ, LPV/r, RDV) to treat COVID-19, ICU care, non-invasive vent w
By vgreene, 14 April, 2020 favipravir (AKA favilavir, fapilavir, Avigan): used in Japan for tx of influenza; first approved drug in China for tx of COVID-19; proposed mechanism: terminates viral replication by binding to RNA-dependent RNA polymerase
By vgreene, 14 April, 2020 Proposed mechanism: dilates pulmonary vasculature, leading to vasodilation and increased oxygenation